Upcoming events – Biomarin’s achondroplasia hope and Apellis’s clash with Alexion
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Upcoming events – Adamas and Ascendis look for new paths forward
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Ascendis shoots higher on pivotal win
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
